110 results about "Agglutinin" patented technology

The invention discloses application of citrullinated endolectin-1 polypeptide in preparation of rheumatoid arthritis diagnosis products, and belongs to the technical field of rheumatoid arthritis diagnosis. The amino acid sequence of the citrullinated endolectin-1 polypeptide is GD-Cit-WSSQQGSKAVYPE, and the amino acid sequence of the citrullinated endolectin-1 polypeptide is GD- The product is used for detecting the content of the anti-citrullinated endolectin-1 polypeptide antibody in a biological sample of a patient, and the antibody level is remarkably different from that of normal healthy people and other common rheumatism immune disease patients easily confused with rheumatoid arthritis in the body of an RA patient. The kit has good sensitivity for common RA, RA with normal ESR and CRP, and anti-CCP antibody / RF negative RA patients, and has good supplementary diagnostic value for RA diagnosis.

The invention discloses a fruit and vegetable exosome extraction method based on ligand fishing. The fruit and vegetable exosome extraction method comprises the following steps: suspending amino-functionalized Fe3O4 (at) SiO2 nanoparticles in a glutaraldehyde solution, and adding activated agglutinin to obtain Fe3O4 (at) SiO2-agglutinin nanoparticles; adding a glutaraldehyde solution into agarose gel to obtain a size exclusion chromatographic column filler; the method comprises the following steps: dispersing Fe3O4 (at) SiO2-lectin nanoparticles in a PBS buffer solution to obtain a uniform suspension, adding the uniform suspension into a size exclusion chromatographic column filler to obtain a uniform slurry, filling the size exclusion chromatographic column with the uniform slurry, and flushing with the buffer solution to form a magnetic bead stationary phase; and loading fruit and vegetable supernatant into a size exclusion chromatographic column, passing through the magnetic bead stationary phase, cleaning residual impurities combined on the exosome-magnetic bead compound by using a buffer solution, and dissociating the exosome from the magnetic beads by using a competitive eluent of the exosome to obtain the high-purity fruit and vegetable exosome. The problem that an existing exosome extraction method is difficult to meet the requirements of high efficiency, simplicity, high purity and high activity at the same time is solved.

The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the complement component C3 gene (C3). The invention also relates to methods of using such RNAi agents to inhibit expression of a C3 gene and to methods of preventing and treating a C3-associated disorder, e.g., cold agglutinin disease (CAD), warm autoimmune hemolytic anemia, and paroxysmal nocturnal hemoglobinuria (PNH), lupis nephritis (LN), bullous pemphigoid, Pemphigus, e.g., Pemphigus vulgaris (PV) and Pemphigus foliaceus (PF), and C3 glomerulopathy.

The invention provides a target antibody or an antigen binding fragment thereof and application thereof, and belongs to the field of antibodies. Wherein the antibody or the antigen binding fragment thereof comprises a heavy chain complementarity determining region HCDR, and the HCDR comprises at least one selected from SEQ ID NO: 1-18 or an amino acid sequence having at least 80% homology with the HCDR. The antibody or the antigen-binding fragment thereof can bind to TIM-1 protein with high specificity and affinity, increase the blocking of TIM-1 activity so as to enable the TIM-1 to interact with ligands such as phosphatidylserine, TIM-4 and galectin-9, and enhance immune response.

The invention relates to the technical field of biological detection, and provides a kit and a method for rapidly detecting a platelet antibody by utilizing a phytolectin solid-phase adsorption method. The detection kit provided by the invention comprises a reaction plate which is coated with phytolectin and adsorbs platelets. According to the method, the platelet of multiple persons is adsorbed by utilizing the non-specific adsorption capacity of the phytolectin, and the adsorbed platelet is directly freeze-dried to the bottom of a microwell plate. During use, a detection result can be obtained only by adding detected plasma / serum into the reaction plate for incubation and then adding an anti-human globule reagent and indicating red blood cells, so that intermediate links of detection are reduced, and standardization and automation of detection are facilitated.

The present invention provides a lipid nanoparticle comprising an entity that contains one or multiple sialic acid (SA) moieties, the entity is preferably a ganglioside, a ganglioside derivative, a ganglioside mimetic, or a combination thereof. The lipid nanoparticle of the present invention can effectively present SA moieties on the surface to bind Siglecs and complement factors to, inter alia, mitigate inflammation. The present invention also provides methods of using said lipid nanoparticle compositions described herein for pharmaceutical applications. For example, the lipid nanoparticles provided herein are useful for treating inflammatory and autoimmune diseases.

Disclosed herein are anti-Galectin-9 antibodies and methods of using in modulating (e.g., increasing) immune responses in a subject, either taken alone or in combination with an immune checkpoint inhibitor, such as a PD-1 inhibitor.

The application provides a galactoside agglutinin 10 (Gal10) crystal and a preparation method and prepared antibody IgY and a pharmaceutical preparation thereof, and belongs to the technical field of medicines. The application uses the galactoside agglutinin 10 crystal as an antigen to prepare an egg yolk neutralizing antibody IgY capable of dissolving the Gal10 crystal, has the effects of improving rhinitis or asthma of a patient, preventing and treating rhinitis and asthma, and is safe, has no side effects, has a long-lasting curative effect, and has no drug resistance, thereby providing a safe, simple, hygienic, effective, economic and personalized treatment mode for prevention and treatment of rhinitis and asthma, and having a high market value.

The present disclosure relates to the field of RNAs for the prevention or treatment of various infectious agents. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection, influenza infection and / or RSV infection and induction of effective coronavirus, influenza virus and / or RSV antigen-specific immune responses, such as antibodies and / or T cell responses. Specifically, in one embodiment, the disclosure relates to a method comprising administering to a subject (i) a bivalent RNA vaccine encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein), and (ii) a tetravalent RNA vaccine encoding a peptide or protein comprising an epitope of hemagglutinin (HA), the present invention relates to a method for inducing an immune response in a subject against a coronavirus S protein, in particular an S protein of SARS-CoV-2, and an influenza protein, in particular an HA protein of influenza A and B viruses.

The application discloses a fucose glycoprotein detection kit, a preparation method thereof and a fucose glycoprotein color developing method. First, a liquid sample is dropped on the surface of the kit, and the sample and test paper are infiltrated through a sample inlet. Under the action of transverse flow force, the sample flows to an observation window along a hydrophilic test paper. The glycoprotein containing alpha 1,2-fucose in the sample is combined with agglutinin 1, and the rest of the sample continues to flow to the next layer of test paper. Then, the glycoprotein containing alpha 1,3-fucose is combined with agglutinin 2, and the rest of the sample flows to the third layer and is combined with agglutinin 3 containing alpha 1,6-fucose glycoprotein. All the combined fucose glycoproteins are combined with agglutinin biotin through their antibodies, and horseradish peroxidase is used for labeling color development, so that quantitative detection of the fucose glycoprotein in the sample is realized. The method has important significance for studying the changes of different connection fucose glycoproteins in cells and body fluids in diseases.

A method for detecting hepatitis B virus comprising a step of bringing a sample into contact with an antibody which binds to a surface antigen protein of hepatitis B virus, and a lectin. The surface antigen protein of hepatitis B virus may be an S protein, and the lectin may be wheat germ agglutinin. The detection method may involve an ELISA measurement and may be used for testing, prophylaxis, or planning treatment of hepatitis B virus, and for screening medicines.

The present invention relates to a compound of formula (I) for use in a method for treatment of a cancer having a higher expression of galectin-1 compared to normal tissue.

The present invention provides a humanized monoclonal antibody against Gal9, and methods of using the antibody to treat cancer, including combination therapies with antagonists of the PD-1 / PD-L1 immune checkpoint.

The present invention relates to a chimeric influenza virus hemagglutinin (HA) polypeptide comprising one or more stem domain sequences fused to one or more globular head domain sequences, each of the one or more stem domain sequences having at least 60% homology to a stem domain consensus sequence of an H1 subtype HA (H1 HA) and / or an H5 subtype HA (H5 HA), each of the one or more globular head domain sequences having at least 60% homology to a globular head domain consensus sequence of an H1 subtype HA (H1 HA) or an H5 subtype HA (H5 HA).

An object of the present invention is to provide a compound having significantly higher antiviral activity than iHA100, an intermediate for producing the compound, a drug containing the highly active compound, etc. A solution of the present invention is a hemagglutinin-binding peptide, a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein the hemagglutinin-binding peptide relates to: (1) a polypeptide composed of the amino acid sequence shown in SEQ ID NO: 1 or 2: Trp-Thr-MeGly-Asp-MePhe-MePhe-Ala-MeAla-His-Tyr-Thr-Val-hydPro-Ala-Cys (SEQ ID NO: 1), Trp-Thr-MeGly-Asp-MePhe-MePhe-Ala-MeAla-His-Tyr-Thr-Val-hydPro-Ala-Cys-Lys (SEQ ID NO: 2), etc.

To provide an osteoclast fusion inhibitor that is highly effective and has few side effects. [Solution] An osteoclast fusion inhibitor containing an anti-galectin-3 neutralizing antibody as an active ingredient.

The invention discloses a universal magnetic nano-enzyme probe for detecting bacteria and viruses, a preparation method, a reagent strip and application, the universal magnetic nano-enzyme probe comprises magnetic Fe3O4 nano-particles and multiple layers of cationic polymer strong positive electricity interlayers loaded on the surfaces of the magnetic Fe3O4 nano-particles, the magnetic Fe3O4 nano-particles serve as inner cores, and the magnetic Fe3O4 nano-particles serve as outer cores. A cationic polymer is used as a connecting layer to adsorb multi-layer small gold iridium alloy nanoparticles (Au (at) Ir), the surfaces of the multi-layer small gold iridium alloy nanoparticles are coupled with wheat germ agglutinin protein molecules, Fe3O4 nanoparticles provide magnetic response ability, and the multi-layer Au (at) Ir provides colorimetric signals, catalytic sites and binding sites. Wheat germ agglutinin (WGA) provides the ability of a label to capture pathogens in a broad spectrum, the Fe-DAu-Ir-WGA probe is combined with an LFA technology, colorimetric signal reading is carried out through ImageJ software, and efficient and ultra-sensitive quantitative detection of multiple pathogens is achieved.

According to the application of a reagent for detecting the biomarker in preparation of a xerophthalmia diagnosis and typing detection reagent, the galectin-9 plays an important role in the occurrence and development process of the xerophthalmia, the expression level of the galectin-9 has a certain correlation with the severity of the xerophthalmia, and the galectin-9 is expected to be used as the biomarker for diagnosis and treatment of the xerophthalmia and can be used for preparing the xerophthalmia diagnosis and typing detection reagent. By detecting the expression condition of Galectin-9 in tears, early and accurate diagnosis of the dry eye and quantitative evaluation of the disease degree are achieved, in addition, Galectin-9 expressed on T cells plays an important role in immune inflammation of the dry eye, ocular surface damage of the dry eye can be relieved by locally intervening Galectin-9 through conjunctiva, and Galectin-9 serves as a novel potential target and has a good application prospect. A new way is opened up for diagnosis and treatment of xerophthalmia, a therapeutic drug or an intervention means developed for Galectin-9 can regulate immune response, inhibit inflammatory response, improve tear secretion and the like from the etiological level, and an existing xerophthalmia treatment mode is expected to be changed, so that the treatment effect is improved, the prognosis of a patient is improved, and the clinical application prospect is broad. The application prospect in the field of diagnosis and treatment of the xerophthalmia is wide, and a certain significance is achieved for improving the overall prevention and treatment level of the xerophthalmia.

A nucleic acid encoding a miniatureized hemagglutinin complex protein, wherein the miniaturized hemagglutinin complex protein has function inhibitory activity against E-cadherin, and wherein the miniaturized hemagglutinin complex protein is selected from the group consisting of: (1) mini-HA consisting of HA1 subcomponent of SEQ ID NO: 10, HA2 subcomponent of SEQ ID NO: 4, and HA3 subcomponent fragment of SEQ ID NO: 2, (2) FL(2+3)-C consisting of HA2 subcomponent of SEQ ID NO: 4 and HA3 component with Strep-Tag (C-terminus) of SEQ ID NO: 44, (3) linked-mini (2+3) / BB of SEQ ID NO: 47, (4) linked-mini (2+3) / CB of SEQ ID NO: 48, (5) linked-mini (2+3) / CB-YFDY of SEQ ID NO: 49, and (6) linked-mini (2+3) / CB-LD / YFDY of SEQ ID NO: 50.

The present invention relates to a retroviral vector, in particular a lentiviral vector, comprising a modified retroviral RNA sequence substituted with a codon and comprising a reduced number of retroviral open reading frames, a method for the production thereof, and uses thereof, and wherein the retroviral vector is pseudo-modeled by hemagglutinin-neuraminidase (HN) and fusion (F) proteins from respiratory paramyxovirus.

Provided herein are methods and compositions for suppressing a foreign body reaction, such as an implant-associated inflammation in a subject, by using an anti-Galectin-3 antibody. Such methods and compositions can be used in various areas applications where an implant is introduced, such as in brain-computer interface (BCI).

The invention relates to the technical field of microalgae feed, and discloses a preparation method and application of microalgae feed, and the preparation method comprises the following steps: S1, extracting hawthorn flavone; s2, extraction of maca unsaturated fatty acid; s3, extracting beta-glucan from the oat bran; s4, extracting pinellia ternate agglutinin; s5, screening of excellent chlorella; according to the preparation method and application of the microalgae feed, the chlorella which is not reported by public literatures is screened out, substances such as pinellia ternate agglutinin extracted from pinellia ternate, beta-glucan extracted from oat bran, flavone extracted from hawthorn, unsaturated fatty acid extracted from maca and the like are combined to serve as a culture medium for culturing the chlorella, an original BG-11 culture medium is replaced, and the microalgae feed is prepared. The chlorella breeding rate is increased; the cultured composite microalgae liquid is used as a liquid feed for livestock and poultry, and compared with a common chlorella feed, the composite microalgae feed can more quickly eliminate toxins such as heavy metals in animal bodies; the weight of animals can be increased, the protein content of meat can be increased, and the fat content can be reduced.

The application belongs to the field of biosensors, and provides a construction method and application of an electrochemical biosensor for quantifying AFP-L3% (AFP-L3 / AFP), and the specific process is as follows: Au@UiO-66 nanocomposites are obtained by using a hydrothermal method and an immersion reduction method, TCEP can open S-S in alpha-fetoprotein to obtain sulfydryl (-SH) and connect to Au@UiO-66, in-situ synthesis of AFP aptamer-copper clusters (Apt-CuNCs) is carried out by using DNA as a template, Apt-CuNCs are used to recognize total AFP, the content of total AFP is determined by using the generated Cu electrochemical signal, then, the Apt-CuNCs are subjected to enzymatic cleavage and stripping by using exonuclease I, alpha-fetoprotein heterogeneity (AFP-L3) is labeled by using lentil agglutinin (LCA) functionalized silver nanoparticles LCA@AgNPs, the content of AFP-L3 is determined by using the generated Ag electrochemical signal, and AFP-L3% can be calculated by combining the data of the two, and the electrochemical biosensor constructed by the method can be used for determining AFP-L3% in human serum.

The invention provides humanized monoclonal antibodies against Gal9, and method of using the antibodies to treat cancer, including combination therapy with antagonists of the PD-1 / PD-L1 immune checkpoint.

The invention relates to a preparation method and application of a probe based on wheat germ lectin. The probe is provided with a core-shell structure, and the core-shell structure is provided with a core and a shell wrapping the outer surface of the core. The core of the core-shell structure is Fe3O4 nanoparticles; the shell comprises a first cationic polymer layer, a gold nanoparticle layer, a second cationic polymer layer, a first quantum dot layer, a third cationic polymer layer, a second quantum dot layer and a wheat germ agglutinin layer which are sequentially coated from the outer surface of the core to the outside. The probe has relatively strong magnetic response capability, colorimetric signals, fluorescence signals and capability of capturing various virus glycoproteins; the MAuDQD-coated WGA-LFA method based on the probe provided by the invention is relatively wide in target detection object range, relatively high in detection sensitivity, relatively high in accuracy and relatively short in detection time.

Disclosed herein are combination therapies for treating hematological malignancies (e.g., acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)) using an antibody that binds human galectin-9 (anti-Gal9 antibody, e.g., G9.2-17) and one or more chemotherapeutic agents, e.g., a Bcl2 inhibitor such as venetoclax, a hypomethylating agent (HMA), or a combination thereof.

The invention relates to the technical field of blood routine examination, and discloses a condensation element removing device and method, and the condensation element removing device comprises a first container, a second container, a filter screen and a carrier. The blood collection tube, the first container and the second container are assembled and uniformly mixed up and down, a detection sample moves back and forth in the blood collection tube and the second container, and when the detection sample flows to the second container from the blood collection tube and the first container, blood cells are intercepted by the filter screen, and blood plasma without the blood cells enters the second container, so that the blood collection tube and the second container are separated from each other. And combining condensed elements in the filtered plasma with an anti-human IgM antibody on the surface of the carrier, fixing the condensed elements on the surface of the carrier, pouring the reacted plasma into a first container and a blood collection tube, fully and uniformly mixing the reacted plasma with blood cells, and carrying out clinical blood routine examination. Theoretically, the process does not cause cell loss, red blood cells do not agglutinate again due to temperature change, and the method is more favorable for helping clinical laboratories to solve the problems of tedious treatment, long time consumption and the like of condensation set samples.

The invention discloses a multi-copy expression construction method of an insecticidal fusion peptide U10-MYRTX-Mri1a-GNA with bacteriostatic activity in pichia pastoris, which comprises the following steps: 1, carrying out reverse PCR (Polymerase Chain Reaction) on a plasmid pGAPZalpha A, introducing a Hind III restriction enzyme cutting site to obtain a plasmid pGAPZalpha A-Hind III, 2, constructing a fragment containing a U10-MYRTX-Mri1a gene, and 3, carrying out multi-copy expression on the fragment containing the U10-MYRTX-Mri1a gene to obtain the insecticidal fusion peptide U10-MYRTX-Mri1a gene. The method comprises the following steps: 1, constructing a U10-MYRTX-Mri1a gene fragment, 2, constructing a U10-MYRTX-Mri1a gene fragment, 3, introducing a GGGSAAA linker and a snowflake agglutinin (GNA)-6 * His label to the C end of the U10-MYRTX-Mri1a gene fragment, 4, constructing a multi-copy expression vector pGAPZalpha A-HindIII-Mira1-GNA * 3, 5, preparing a pichia pastoris competent cell X33, and 6, carrying out electrochemical conversion to obtain a genetically engineered bacterium X33-pGAPZalpha A-HindIII-Mira1-GNA * 3. According to the invention, a linearized plasmid is transferred to pichia pastoris X33, so that a genetically engineered bacterium for expressing the fusion peptide U10-MYRTX-Mri1a-GNA is obtained.

Provided herein are antibodies that target Galectin-3. Such antibodies are used in methods of treating epilepsy and related neurological disorders, such as Alzheimer's disease (AD) and Parkinson's disease (PD).